07:00 , Jul 20, 2015 |  BC Week In Review  |  Clinical News

Live tumor cell diagnostic: Pilot trial data

A blinded analysis of 104 tumor tissue samples obtained from radical prostatectomies from a U.S. proof-of-concept (POC) trial showed that Cellanyx’s live tumor cell phenotypic biomarker test had 88% sensitivity and 81% specificity for discriminating...